Pamela Bolyanatz, NP
Nurse Practitioner · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 1 carrier
- Office
- 1
- Since medical school
- 22 years
- Graduated 2004
Offices
1 location · University of California San Francisco · 1,780 clinicians in this group
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Pamela Bolyanatz’s office at (415) 476-1000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
State licence records
1 licence
- Illinois 209005489Advanced Practice Registered Nurse · since 2005 · expires 2022-08-31Not RenewedNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Drugs they prescribed that Part D paid
$1,065
Pharmacies billed $1,065 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 40% of their Part D prescriptions (24 of 60) in 2024. A higher opioid share than 9 in 10 peers; the typical nurse practitioner clinician is at 0%.
58 generic and fewer than 11 brand-name prescriptions · $1,065 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Gabapentin | 12 | $111 | $9 |
Year by year
| 2024 | 60 | 22 | 40% (24) | None | $1,065 |
| 2018 | 23 | None | None | 0% | $559 |
| 2017 | 23 | None | 70% (16) | None | $1,401 |
| 2016 | 14 | None | None | 0% | $1,612 |
| 2015 | 14 | None | 79% (11) | None | $2,351 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
Money from drug and device companies
$45 in 2025
| 2025 | 1 | 1 | None | $45 |
| 2023 | 1 | 1 | None | $67 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Salix Pharmaceuticals a division of Bausch Health US | Relistor | $45 | 1 payment
|
See the published payment
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-11-11 | Relistor | $45 |
See earlier years (2023)
2023: $67
| Salix Pharmaceuticals a division of Bausch Health US | Relistor | $67 | 1 payment
|
Professional record
- NPI
- 1477571347
- Licence
- CA 306471, IL 209-005489Illinois 209005489: Not Renewed
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 363LF0000X (363LF0000X); Medical oncology (207RX0202X)
- Mailing address
- 3333 California St, San Francisco, CA, 94118
- NPI first listed
- 2006-07-18
- NPI last updated
- 2019-06-18
This is when the NPI record was last certified, not a medical board exam.